GBIO(GBIO)
GBIO
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E | FY2028E | FY2029E |
|---|---|---|---|---|
| Revenue Avg | $4M | $11M | $6M | $6M |
| Low | $4M | $11M | $6M | $6M |
| High | $4M | $11M | $6M | $6M |
| EBITDA Avg | $765,866 | $2M | $1M | $1M |
| Low | $765,866 | $2M | $1M | $1M |
| High | $765,866 | $2M | $1M | $1M |
| EBIT Avg | $765,866 | $2M | $1M | $1M |
| Low | $765,866 | $2M | $1M | $1M |
| High | $765,866 | $2M | $1M | $1M |
| Net Income Avg | $-25M | $-13M | $4M | $2M |
| Low | $-25M | $-13M | $4M | $2M |
| High | $-25M | $-13M | $4M | $2M |
| EPS Avg | $-3.72 | $-1.95 | $0.53 | $0.36 |
| Low | $-3.72 | $-1.95 | $0.53 | $0.36 |
| High | $-3.72 | $-1.95 | $0.53 | $0.36 |
| Analysts (Rev / EPS) | 3 / 1 | 1 / 1 | 1 / 1 | 1 / 1 |
| Metric | Q3 2026 | Q4 2026 |
|---|---|---|
| Revenue Avg | $77,350 | $77,350 |
| Low | $77,350 | $77,350 |
| High | $77,350 | $77,350 |
| EBITDA Avg | $15,469 | $15,469 |
| Low | $15,469 | $15,469 |
| High | $15,469 | $15,469 |
| EBIT Avg | $15,469 | $15,469 |
| Low | $15,469 | $15,469 |
| High | $15,469 | $15,469 |
| Net Income Avg | $-6M | $-6M |
| Low | $-6M | $-6M |
| High | $-6M | $-6M |
| EPS Avg | $-0.95 | $-0.93 |
| Low | $-0.95 | $-0.93 |
| High | $-0.95 | $-0.93 |
| Analysts (Rev / EPS) | 1 / 1 | 1 / 1 |